Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q3 FY2025 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Feb 13, 2025
Slide 1: Stock exchange cover letter for Q3 FY2025 investor presentation
13th February 2025 IOLCP/CGC/2025 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai- 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Investor Presenta
Slide 2: IOL Chemicals and Pharmaceuticals Q3 FY2025 Investor Presentation
IOL Chemicals And Pharmaceuticals Limited Q3 FY2025 Investor Presentation February 2025
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals and Pharmaceuticals Limited solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any
Slide 4: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview • About IOL Chemicals and Pharmaceuticals • Standalone Quarterly & Nine Monthly • The Journey Ltd. Income Statement • Core management team • Q3 & 9M FY2025 Performance • Standalone Income - Sustained revenue • Board o
Slide 5: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Key Highlights Team size of 2800+ employees Credit Rating: A+, outlook; stable (Care Ratings Lim
Slide 6: Q3 & 9M FY25 Performance
Q3 & 9M FY25 Performance • The Board declared an Interim Dividend of Rs. 4/- Q3FY25 Financial Performance per equity share of face value of Rs 10 each. • Post approval from Shareholders, Record Date has ₹ 527 Cr ₹ 51 Cr 9.7% been fixed for Mar 11, 2025 ’ for sub-division/split Total Income EBITDA EB
Slide 7: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (₹ crore) Pharma Pharma Segment Segment (₹ (₹ crore) crore) 233 232 223 6 400 60 207 206 301 200 5 287 295 296 294 5 300 4 40 150 39 3 200 35 2 2 35 100 2 25 26 20 1 1 50 100 1 0 0 0 0 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q3FY24 Q4FY24 Q1FY25 Q2FY
Slide 8: Financial Highlights
Financial Highlights 7
Slide 9: Standalone Quarterly & Nine Monthly Income Statement
Standalone Quarterly & Nine Monthly Income Statement Particulars (₹ Cr) Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9M FY25 9M FY24 YoY Revenues 523.3 520.4 0.6% 525.8 -0.5% 1,551.4 1,628.9 -4.8% Other Income 4.1 8.4 6.4 17.9 22.6 Total Income 527.4 528.8 -0.3% 532.2 -0.9% 1,569.3 1,651.5 -5.0% Total Expenses 4
Slide 10: Standalone Income - Sustained revenue
Standalone Income - Sustained revenue Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 9M FY25 Revenues 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 2,132.8 1,551.4 Other Income 10.4 16.0 24.3 32.0 25.6 30.1 17.9 Total Income 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 2,162.9 1,569.3 Total Expenses 1,275.7
Slide 11: Standalone Balance Sheet - Building assets
Standalone Balance Sheet - Building assets Balance Sheet (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 H1FY25 Shareholders' Funds 474.3 813.5 1260.4 1390.3 1506.6 1611.3 1658.8 Long-term Debt 284.0 56.0 0.0 0.0 0.0 0.0 0.0 Total Non-current Liabilities 20.8 79.7 59.1 56.6 58.1 72.9 76.1 Total Current Liabili
Slide 12: Standalone Cash Flow Statement
Standalone Cash Flow Statement Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 H1FY25 Profit before tax 336.2 533.2 571.4 222.8 189.5 182.6 65.2 Adjustments for: Non Cash Items / Other 82.4 51.9 27.2 33.1 44.4 60.1 37.5 Investment or Financial Items Operating profit before working capital changes 4
Slide 13: 5-years Performance
5-years Performance Operational Revenue (₹ Cr) EBITDA (₹ Cr) and EBITDA Margin (%) PAT (₹ Cr) and PAT Margin (%) 2,216 2,243 2,163 30.9% 30.9% 22.3% 1,911 1,991 18.9% 1569 12.1% 13.0% 11.2% 10.0% 7.5% 6.2% 6.3% 4.4% 590 616 288 252 262 157 361 445 166 140 135 69 FY20 FY21 FY22 FY23 FY24 9M FY25 FY20
Slide 14: Diversified revenue base
Diversified revenue base FY20 FY24 9M FY25 682, 36% 865, 41% 661, 43% 431, 20% 306, 20% 167, 9% 1046, 55% 837, 39% 584, 37% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's 13 * Amt in ₹ crore
Slide 15: Company Overview
Company Overview 14
Slide 16: The Journey
The Journey ▪ 2009 - Commencement of ▪ 1996 - Commencement of ▪ 2015 - USFDA, EIR for ▪ Paracetamol capacity IBB, MCA and Acetyl Ethyl Acetate Plant Ibuprofen ▪ 2019 - Unit-06 for has been increased to Chloride Plants ▪ 1999 - Commencement of ▪ 2016 - Unit-03 for new Pantoprazole (Dedicated) 3,600 T
Slide 17: Core management team
Core management team Varinder Gupta (Managing Director) Wide and rich experience of more than 37 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry Vikas Gupta oversight has paved a way for innovation and excellence (Joint Managing Dire
Slide 18: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 19: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility EUGMP Certification in Certified Halal in ISO 9001:2015, since 2015, recertified in Certificate of Suitability Certificate of DMF 2013, 2017 & accordance with Shariah 14001:2015 & 2019 from EDQM Registration From MFDS Recertification in 2020
Slide 20: Business Overview
Business Overview OL Chemicals And Pharmaceuticals Limlte¢
Slide 21: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~30% Global share and the only company worldwide being backward integrated for all Intermediate stages of Ibuprofen having a capacity of 12000+ MT • Dedicated USFDA approved facilities for Ibuprofen • Among the
Slide 22: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOL first commenced manufacturing Ethyl Acetate in 1996, with initial capacity of 3000 TPA. Today, the Company has grown this business to become major producer of Ethyl Acetate, with a production capacity of 1,00,000 TPA • Strengthening the backwar
Slide 23: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology 3 Dedicated and multiproduct blocks involved in manufacturing of APIs 5 system, PSA Nitrogen & P
Slide 24: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment • State of the art Zero liquid Discharge (ZLD) Facility • Committed to ensure that our operations have minimal 100% Water impact on the environment neutral • Constantly monitoring environmental footprints and implementing relevant i
Slide 25: Industry Overview
Industry Overview 24
Slide 26: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • The Indian API market is expected to grow at a CAGR of 13.7% over the four years • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. $1.6 8-10% $2.4 Trilli
Slide 27: Specialty Chemicals – an era of sustained robust growth
Specialty Chemicals – an era of sustained robust growth Short-term growth to remain subdued… • Demand headwinds from export markets, China’s rising supplies and inventory destocking have impacted margins & profitability of Indian players • Expectations of sluggish global growth, oversupplied industr
Slide 28: Way Forward
Way Forward 27
Slide 29: Four pronged strategy for growth
Charting a path to success Four pronged strategy for growth Improved asset Focus on Expanding Non- Capacity expansion utilization Regulated Markets Ibuprofen Business in Pharma & Chemicals The share of Increased contribution Added more than 10 The Company’s regulated of non-Ibuprofen products since
Slide 30: Expanding the non-Ibuprofen business
Expanding the non-Ibuprofen business (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an installed Regulatory Filings: CEP capacity of 3,600 MT/Annum, with approved; US DMF filed a backward integration process (Antiplatelet drug, used in cardiovascular (Anticonsu
Slide 31: Thank You
THANK YOU Company : Investor Relations Advisors : Adfactors PR Pvt. Ltd. IOL Chemicals and Pharmaceuticals Ltd. Darshan Mankad darshan.mankad@adfactorspr.com Mr. Pardeep Kumar Khanna, CFO Hanishi Shah pardeepkhanna@iolcp.com hanishi.shah@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q3 FY2025 Earnings Presentation on 6ix